Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | UBE2N | P61088 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | IDE | P14735 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838017 | 1.00 | HTR6 (0.64) | HTR6ALKALDH1A1MAPTRECQL | |
| SCHEMBL14037386 | 0.87 | MAPT (0.55) | HTR6ALKALDH1A1MAPTRECQL | |
| SCHEMBL850128 | 0.83 | ALOX5 (0.62) | HTR6ALKL3MBTL1CYP19A1KDM4E | |
| SCHEMBL9054387 | 0.82 | HTR6 (0.67) | HTR6ALKL3MBTL1CYP19A1KDM4E | |
| SCHEMBL29809802 | 0.82 | MAPT (0.62) | HTR6ALDH1A1MAPTRECQLKDM4E | |
| SCHEMBL946516 | 0.81 | HTR6 (0.74) | HTR6ALKL3MBTL1CYP19A1KDM4E | |
| SCHEMBL7583708 | 0.80 | HTR6 (0.51) | HTR6ALKCYP19A1KDM4EUBE2N | |
| SCHEMBL14037385 | 0.78 | ALDH1A1 (0.56) | HTR6ALDH1A1MAPTRECQLIDE | |
| SCHEMBL7254162 | 0.78 | HTR6 (0.63) | HTR6ALDH1A1MAPTRECQL | |
| SCHEMBL15250049 | 0.78 | HTR6 (1.00) | HTR6ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| EP-1109831-B1 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | LYTIX BIOPHARMA AS (NO) | 2011-01-12 | — | — | EP | disclosed |
| US-20080287346-A1 | Bioactive peptides | SVENDSEN JOHN SIGURD | 2008-11-20 | — | — | US | disclosed |
| US-7439228-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2008-10-21 | — | — | US | disclosed |
| US-20080019993-A1 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2008-01-24 | — | — | US | disclosed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | disclosed |
| US-20030148936-A1 | Bioactive peptides | ALPHARMA AS. | 2003-08-07 | — | — | US | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287346-A1 | Bioactive peptides | VIP, NGLY1, IAPP | HTR6 4337/4885ALK 3164/4885ALDH1A1 4821/4885 |
| US-20080019993-A1 | Inhibition of tumour growth | STING1, VIP, MIF | HTR6 4618/4885ALK 2736/4885ALDH1A1 4759/4885 |
| US-20030148936-A1 | Bioactive peptides | VIP, NGLY1, HM13 | HTR6 2778/4885ALK 1526/4885ALDH1A1 4545/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | HTR6 4734/4885ALK 3677/4885ALDH1A1 4445/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | HTR6 4531/4885ALK 2705/4885ALDH1A1 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.